SMMT — Summit Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $17.31bn
- $16.90bn
- 36
- 20
- 89
- 46
Annual cashflow statement for Summit Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -52.7 | -88.6 | -78.8 | -615 | -221 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2.42 | 14.7 | 27.3 | 540 | 63.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.619 | -0.067 | 8.62 | -2.37 | 15.5 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -48.1 | -72.6 | -41.6 | -76.8 | -142 |
| Capital Expenditures | -0.421 | -0.306 | -0.624 | -0.128 | -0.139 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | — | — | -588 | -205 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.421 | -0.306 | -0.624 | -588 | -205 |
| Financing Cash Flow Items | -0.048 | -0.172 | -0.155 | -0.619 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 50.6 | 77.9 | 620 | 86.5 | 381 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.58 | 5.37 | 577 | -577 | 33.8 |